hematopoietic system phenotype

• impaired natural killer cell mediated cytotoxicity
  • normal level of target cell killing can be restored by in vivo pretreatment with IL-18 for two days or the addition of IL-18 to the co-culture
  (MGI Ref ID J:46514)
  • the killing activity of splenic NK cells is about 2/3^rds that of wild-type mice as measured by in vitro co-culturing with YAC-1 target cells
  (MGI Ref ID J:46514)

• abnormal T-helper 1 physiology
  • in vivo Th1 cell response is impaired as indicated by the low amounts of IFN-gamma produced by T cells in response to M. bovis antigens
  (MGI Ref ID J:46514)

immune system phenotype

• decreased interferon-gamma secretion
  • splenic T cells produce about 1/4^th the amount of IFN-gamma as T cells from wild-type mice 14 days after injection with heat killed M. Bovis
  (MGI Ref ID J:46514)

• impaired natural killer cell mediated cytotoxicity
  • normal level of target cell killing can be restored by in vivo pretreatment with IL-18 for two days or the addition of IL-18 to the co-culture
  (MGI Ref ID J:46514)
  • the killing activity of splenic NK cells is about 2/3^rds that of wild-type mice as measured by in vitro co-culturing with YAC-1 target cells
  (MGI Ref ID J:46514)

• abnormal T-helper 1 physiology
  • in vivo Th1 cell response is impaired as indicated by the low amounts of IFN-gamma produced by T cells in response to M. bovis antigens
  (MGI Ref ID J:46514)

immune system phenotype

• increased susceptibility to bacterial infection induced morbidity/mortality
  • mice died before day 12 after inoculation with C. rodentium
  (MGI Ref ID J:161073)

mortality/aging

• increased susceptibility to bacterial infection induced morbidity/mortality
  • mice died before day 12 after inoculation with C. rodentium
  (MGI Ref ID J:161073)

craniofacial phenotype

• alveolar process atrophy
  • 3 fold increase in alveolar bone loss at 30 weeks relative to mice at 6 and 16 weeks
  (MGI Ref ID J:147935)

immune system phenotype

• abnormal macrophage physiology
  • fewer than expected macrophages in the dermis of carcinogen treated skin
  (MGI Ref ID J:111568)

• decreased interleukin-17 secretion
  • barely detectable levels of IL17 in the skin after carcinogen treatment unlike wild-type mice which express high levels of IL17
  (MGI Ref ID J:111568)

• decreased susceptibility to type IV hypersensitivity reaction
  • specific foot pad swelling 48 hours after challenge with methylated bovine serum albumin is inhibited by 47 +/- 3% compared to wild-type mice; however, cytotoxic T lymphocyte responses are similar to wild-type
  (MGI Ref ID J:120806)

• increased susceptibility to bacterial infection
  • vaccination does not produce a protective response to M. tuberculosis
  (MGI Ref ID J:120806)

• abnormal lymphocyte physiology
  • lymph node cells from keyhole limpet hemocyanin (KLH) immunized mice are severely impaired in their ability to produce IFNG when cultured with KLH; however, their production of IL4 is increased
  (MGI Ref ID J:120806)

• decreased circulating interferon-gamma level
  • serum levels of IFNG in LPS-injected mice are only 17 +/- 5% of LPS-induced controls
  (MGI Ref ID J:120806)

• abnormal granulocyte physiology
  • fewer than expected granulocytes in the dermis of carcinogen treated skin
  (MGI Ref ID J:111568)

• abnormal NK cell physiology
  • mean NK lytic activity is about 66% of controls; however when cultured with IL2 lytic activity is similar to controls
  (MGI Ref ID J:120806)

• abnormal CD8-positive, alpha-beta T cell physiology
  • dramatic increase in the number of cytotoxic CD8+ cells in the dermis and epidermis of carcinogen treated skin
  (MGI Ref ID J:111568)

growth/size/body region phenotype

• alveolar process atrophy
  • 3 fold increase in alveolar bone loss at 30 weeks relative to mice at 6 and 16 weeks
  (MGI Ref ID J:147935)

mortality/aging

• increased sensitivity to xenobiotic induced morbidity/mortality
  • increase in mortality following a single dose of N-methyl-N-nitrosourea (MNU) compared to similarly treated wild-type controls
  (MGI Ref ID J:91927)

neoplasm

• decreased incidence of tumors by chemical induction
  • however, there is an increase in the incidence of tumors following intradermal challenge with PDV squamous carcinoma cells
  (MGI Ref ID J:111568)
  • resistant to induction of papillomas compared to wild-type mice after treatment with DMBA and TPA in a 2 step skin carcinogenesis protocol
  (MGI Ref ID J:111568)

skeleton phenotype

• alveolar process atrophy
  • 3 fold increase in alveolar bone loss at 30 weeks relative to mice at 6 and 16 weeks
  (MGI Ref ID J:147935)

hematopoietic system phenotype

• abnormal NK cell physiology
  • mean NK lytic activity is about 66% of controls; however when cultured with IL2 lytic activity is similar to controls
  (MGI Ref ID J:120806)

• abnormal macrophage physiology
  • fewer than expected macrophages in the dermis of carcinogen treated skin
  (MGI Ref ID J:111568)

• abnormal granulocyte physiology
  • fewer than expected granulocytes in the dermis of carcinogen treated skin
  (MGI Ref ID J:111568)

• abnormal CD8-positive, alpha-beta T cell physiology
  • dramatic increase in the number of cytotoxic CD8+ cells in the dermis and epidermis of carcinogen treated skin
  (MGI Ref ID J:111568)

• abnormal lymphocyte physiology
  • lymph node cells from keyhole limpet hemocyanin (KLH) immunized mice are severely impaired in their ability to produce IFNG when cultured with KLH; however, their production of IL4 is increased
  (MGI Ref ID J:120806)

homeostasis/metabolism phenotype

• decreased circulating interferon-gamma level
  • serum levels of IFNG in LPS-injected mice are only 17 +/- 5% of LPS-induced controls
  (MGI Ref ID J:120806)

• decreased incidence of tumors by chemical induction
  • however, there is an increase in the incidence of tumors following intradermal challenge with PDV squamous carcinoma cells
  (MGI Ref ID J:111568)
  • resistant to induction of papillomas compared to wild-type mice after treatment with DMBA and TPA in a 2 step skin carcinogenesis protocol
  (MGI Ref ID J:111568)

• increased sensitivity to xenobiotic induced morbidity/mortality
  • increase in mortality following a single dose of N-methyl-N-nitrosourea (MNU) compared to similarly treated wild-type controls
  (MGI Ref ID J:91927)

hematopoietic system phenotype

• abnormal CD4-positive, alpha-beta T cell physiology
  • 75 days after infection Il4 mRNA expression in CD4+ cells is 100-fold higher than in wild-type
  (MGI Ref ID J:34164)
  • draining lymph node cells in L. major infected mice produce significantly more IL4 compared to IFNG in contrast to wild-type mice which express more IFNG than IL4
  (MGI Ref ID J:34164)
  • 75 days after infection Ifng mRNA expression in CD4+ cells is more than 50-fold lower than in wild-type
  (MGI Ref ID J:34164)

immune system phenotype

• abnormal CD4-positive, alpha-beta T cell physiology
  • 75 days after infection Il4 mRNA expression in CD4+ cells is 100-fold higher than in wild-type
  (MGI Ref ID J:34164)
  • draining lymph node cells in L. major infected mice produce significantly more IL4 compared to IFNG in contrast to wild-type mice which express more IFNG than IL4
  (MGI Ref ID J:34164)
  • 75 days after infection Ifng mRNA expression in CD4+ cells is more than 50-fold lower than in wild-type
  (MGI Ref ID J:34164)

• decreased susceptibility to type IV hypersensitivity reaction
  • do not show any delayed type hypersensitivity response to application of Leishmania antigen to the uninfected footpad 41 days after initial infection with L. major
  (MGI Ref ID J:34164)

• increased susceptibility to parasitic infection
  • 75 days after infection with L. major parasite numbers in the draining lymph nodes are increased 400-fold compared to wild-type mice
  (MGI Ref ID J:34164)
  • develop large lesions unlike wild-type 129S1/Sv mice after infection with Leishmania major
  (MGI Ref ID J:34164)